Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for the Re-emerging Human Monkeypox Virus

Wooseong Lee,Yu-Jin Kim,Su Jin Lee,Dae-Gyun Ahn,Seong-Jun Kim
DOI: https://doi.org/10.4014/jmb.2306.06033
2023-07-25
Journal of Microbiology and Biotechnology
Abstract:Monkeypox (Mpox) virus, a member of the <i>Poxviridae</i> family, causes a severe illness similar to smallpox, which is characterized by symptoms such as high fever, rash, and pustules. Human-to-human transmission cases have been reported but remained low since the first recorded case of human infection occurred in the Congo in 1970. Recently, Mpox has re-emerged, leading to an alarming surge in infections worldwide since 2022, originating in the United Kingdom. Consequently, the World Health Organization (WHO) officially declared the '2022-23 Mpox outbreak'. Currently, no specific therapy or vaccine is available for Mpox. Therefore, patients infected with Mpox are treated using conventional therapies developed for smallpox. However, the vaccines developed for smallpox have demonstrated only partial efficacy against Mpox, allowing viral transmission among humans. In this review, we discuss the current epidemiology of the ongoing Mpox outbreak and provide an update on the progress made in diagnosis, treatment, and development of vaccines for Mpox.
biotechnology & applied microbiology,microbiology
What problem does this paper attempt to address?